Skip to content

Eye Health Center

Pinkeye Treatment May Be on the Horizon

Experimental Eye Drops Could Prevent Infection, Researchers Say
Font Size
A
A
A
By
WebMD Health News
Reviewed by Laura J. Martin, MD

Sept. 30, 2011 -- There are no recommended antiviral drugs to treat a highly contagious form of viral conjunctivitis called pinkeye.

Outbreaks result in millions of lost school and workdays each year in the U.S. as patients stay home to avoid infecting others while the condition improves.

Now early research from Sweden suggests that an experimental eye drop might stop viral pinkeye in its tracks and keep family members, schoolmates, coworkers, and other close contacts of patients from becoming infected.

The drops have not been studied in humans, but researchers say they are optimistic the treatment will prevent infection by tricking the virus into binding to artificial surfaces in the drops designed to mimic key cells in the eye.

Once this happens, the entrapped virus should be easily washed from the eye in tears, says researcher Ulf Ellervik, PhD, who is a professor of microbiology at Sweden’s Umea University.

“Pinkeye is a very troublesome condition,” Ellervik says. “If one family member gets it, usually everyone gets it."

Viral Pinkeye Drop May Prevent Infection

Most often caused by the same virus responsible for the common cold, viral pinkeye is an infection of the part of the eye that produces mucus and tears, known as the conjunctiva.

According to the American Academy of Ophthalmology, more than 3 million school days are lost each year as a result of pinkeye.

The experimental treatment targets adenoviruses 8, 19, and 37, which cause most viral conjunctivitis.

In earlier work, the Swedish research team showed that these viruses must bind to sialic acid for infection to occur.

“What we did in this research was create an artificial surface that tricks the virus into binding to it instead of the host,” Ellervik says.

The study, which appears in the latest issue of the Journal of Medicinal Chemistry, was funded by Adenovir Pharma AB, which was founded by Umea University researchers to develop the treatment, according to the company’s web site.

Human Studies Next Step

Adenovir Pharma CEO Bjorn Dellgren says the company hopes to begin phase I human studies of the eye drops by the end of the year or early next year once the trials are approved.

Today on WebMD

Woman holding tissue to reddened eye
Learn about causes, symptoms, and treatments.
eye
Simple annoyance or the sign of a problem?
 
red eyes
Symptoms, triggers, and treatments.
blue eye with contact lens
Tips for wearing and caring.
 
Understanding Stye
Article
human eye
Article
 
eye
Video
eye exam timing
Video
 
vision test
Tool
is vision correction surgery for you
Article
 
high tech contacts
Article
eye drop
Article
 

Special Sections